CASGEVY is expecting more approvals from various global regulatory bodies, potentially increasing the total addressable patients. The management team is attempting to make CASGEVY more accessible ...
Wilmington, DE, (MARCH 21, 2022) – A new study from scientists at ChristianaCare’s Gene Editing Institute is advancing the safety and efficacy of using CRISPR gene editing in patient treatments by ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
CRISPR technology has not yet been FDA approved for Cystic Fibrosis or Muscular Dystrophy and is still being investigated for use against these diseases. Gene editing has enormous potential to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback